Načítá se...
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2–4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this l...
Uloženo v:
| Vydáno v: | Drug Des Devel Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5373840/ https://ncbi.nlm.nih.gov/pubmed/28392676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S108872 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|